What is Regeneron's primary source of revenue and how is it trending?

Regeneron's primary revenue streams are contract research and development, and contract manufacturing. Total revenue decreased in the second quarter of 2001 compared to the same period in 2000, primarily due to lower contract research and development revenue from key partnerships, while contract manufacturing revenue saw a slight increase.

How is the company managing its expenses, particularly R&D?

The company is significantly increasing its investment in research and development, with R&D expenses rising to $19.6 million in Q2 2001 from $15.4 million in Q2 2000. This reflects the ongoing costs associated with advancing its pipeline of drug candidates through clinical and preclinical stages.

What is the company's financial position in terms of liquidity?

Regeneron significantly improved its liquidity through a public offering in March/April 2001, resulting in cash, cash equivalents, and marketable securities totaling $290.5 million as of June 30, 2001. The company believes this will be sufficient to fund operations through at least 2002.

Are there any significant developments in the company's drug pipeline?

Yes, the company initiated a Phase III clinical program for AXOKINE, a potential obesity treatment, in July 2001. Other key pipeline candidates include IL-1 Trap, IL-4/IL-13 Trap, and VEGF Trap, which are in various stages of development.

REGN 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter ending June 29, 2001. The company continues to operate at a loss, reflecting its significant investment in research and development. Total revenue decreased in the second quarter of 2001 compared to the prior year, primarily due to lower contract research and development revenue from collaborations with Procter & Gamble and Amgen-Regeneron Partners, partly offset by an increase in contract manufacturing revenue from Merck. Operating expenses increased, driven by higher research and development spending on ongoing clinical and preclinical programs, including AXOKINE for obesity. Despite the increased expenses and continued net loss, the company strengthened its balance sheet through a public offering of common stock in March 2001, significantly increasing its cash and cash equivalents. Regeneron believes its current capital resources are sufficient to fund operations through at least 2002.

Key Highlights

1Total revenue for the quarter decreased to $5.8 million from $14.5 million in the prior year's second quarter, mainly due to reduced contract research and development revenue.
2Research and development expenses increased to $19.6 million from $15.4 million year-over-year, reflecting ongoing investment in clinical and preclinical programs.
3Net loss for the quarter was $14.8 million ($0.34 per share), an increase from a net loss of $2.9 million ($0.08 per share) in the prior year's second quarter.
4The company raised approximately $156.7 million in net proceeds from a public offering of common stock in March/April 2001, significantly bolstering its cash position.
5Cash, cash equivalents, and marketable securities stood at $290.5 million as of June 30, 2001, providing a substantial liquidity buffer.
6The Phase III clinical program for AXOKINE (obesity treatment) was initiated in July 2001, involving approximately 2,000 patients.
7Amgen-Regeneron Partners discontinued clinical development of BDNF for ALS, impacting revenue from that collaboration.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions